Telehealth pharmacy fulfillment: how OrbitRx gets a prescription from the provider to the patient's door

1. The provider signs

After Orbit Intake scores the questionnaire and a network or brand-supplied provider completes the visit, the provider writes the prescription inside OrbitOS.

• Drug, strength, directions, quantity and refills are structured fields, not free text, which is what lets the next step work without re-keying.
• For scheduled drugs, OrbitRx requires EPCS two-factor authentication at signature: something the prescriber knows and something they hold, tied to an identity that was proofed when they were credentialed.
• MyOrbitHealth does not practice medicine; the signing provider is accountable for the clinical decision.

2. Surescripts carries it

The signed prescription leaves as a standard electronic message over Surescripts, the national e-prescribing network that connects prescriber software to pharmacy management systems.

• This replaces the fax-and-callback loop that delays first shipments in programs built on generic video tools.
• It also creates a transaction record that ties a specific prescriber to a specific order, which is what a pharmacy board, a payer or LegitScript will ask for.
• Because Surescripts reaches every major U.S. pharmacy, a patient who prefers to pick up at the chain down the street can; a patient who wants home delivery goes to the network.

3. Routing selects the pharmacy

For network orders, routing considers two things before anything else: does the pharmacy hold the license required to ship into the patient's state, and does it stock or compound the product the provider ordered.

• Licensure is matched per ship-to state at routing time, not assumed from a master list.
• Product fit decides between a retail pharmacy for a branded or generic manufactured drug and a 503A compounding pharmacy for a patient-specific preparation.
• The pharmacist-in-charge then performs the usual verification of the prescription against the patient profile before filling.
• If no pharmacy in the network can lawfully fill a given order for a given state, the order does not ship, and the provider and brand are notified rather than left guessing.

4. Cold chain and carrier hand-off

Medications with refrigerated storage requirements, which include the major GLP-1 injectables, are packed in qualified insulated shippers with refrigerant sized for the route and season.

• Pharmacies in the network ship to all 50 states and schedule carrier pickup to avoid weekend dwell for refrigerated orders.
• Lot or batch number, expiration or beyond-use date and storage instructions appear on the label.
• We do not quote delivery timelines on this page; transit depends on the carrier, the destination and the pharmacy's fill queue, and we would rather you see the live tracking than a marketing average.

5. Tracking to the portal

When the pharmacy marks the order dispensed and hands it to the carrier, the status and tracking number appear in the branded patient portal and native app.

• The dispense event is written to the chart in OrbitOS and, if the brand integrates, delivered to its systems as a signed prescription.dispensed webhook.
• Failed deliveries, temperature excursions and side-effect reports route to the pharmacy and the provider respectively, not to the brand's support desk, because those are pharmacy and clinical questions.
• The brand's team handles what it should: logistics questions, program changes and retention.

When retail routing applies

A branded or generic manufactured drug, from finasteride and sildenafil to Wegovy and Zepbound, is dispensed by a retail pharmacy, either the patient's chosen local pharmacy over Surescripts or a mail-order pharmacy in the network.

There is nothing to compound. The pharmacy's cost for the product passes through at 0% markup, and the patient may also choose to use insurance at their local pharmacy for a covered manufactured drug.

When 503A compounding applies

A 503A pharmacy compounds a preparation for an individual patient on the basis of a prescription from a licensed prescriber.

• It is appropriate when the provider documents a patient-specific need the manufactured product does not meet: a different strength for titration, a formulation without an excipient the patient cannot tolerate, a combination that is not sold as a single product, or a dosage form that is not manufactured.
• The prescriber's documented rationale is what makes the order fillable, so the provider decides, and the pharmacy confirms.
• 503A pharmacies are state-board regulated and fill one prescription for one patient; they are not manufacturers.
• The MyOrbitHealth network is made up of 503A compounding pharmacies and retail pharmacies.

Why the distinction matters for a brand

The two models carry different regulatory exposure, different advertising rules and different margin structures.

Marketing a compounded preparation as if it were the FDA-approved brand, or implying that a compounded drug is FDA-approved, is the fastest route to a warning letter and a lost ad account. The founder-level explanation of the two pharmacy types is at /blog/503a-vs-503b, and the questions to ask before contracting with any compounding pharmacy, including what the platform asks on your behalf, are at /blog/compounding-pharmacy-partnerships.

Compounded vs branded after the shortage resolutions

During the drug shortages, compounding pharmacies could prepare essentially a copy of semaglutide and tirzepatide products under the shortage exceptions in federal law.

• FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, and the grace periods it set for compounders have since passed.
• The practical result is that compounding a GLP-1 now generally depends on a patient-specific clinical rationale documented by the prescriber, not on the shortage.
• FDA has also acted against telehealth companies over how compounded GLP-1s are advertised, and policy in this area continues to move, so treat anything you read, including this page, as a snapshot to verify against fda.gov.

How OrbitRx routes a GLP-1 order today

Where the provider prescribes a branded product, the order routes to a retail or mail-order pharmacy that stocks it, cold chain, at pass-through cost.

• Where the provider documents a patient-specific basis for a compounded preparation, the order routes to a 503A pharmacy in the network that is licensed for the ship-to state and performs sterile compounding.
• The brand does not choose the route; it chooses the program it offers and the price it charges.
• Titration-driven refills follow the provider's schedule rather than a subscription timer, so a dose change triggers a new prescription event rather than a silent repeat shipment.

What to read before you launch a GLP-1 program

Our fulfillment guide at /blog/glp1-pharmacy-fulfillment walks the full pipeline stage by stage, including the cold-chain and excursion policies a GLP-1 pharmacy should have.

The comparison at /blog/compounded-tirzepatide-vs-zepbound explains how operators think about branded versus compounded tirzepatide for patients and for the program's economics. Both are updated as federal policy changes.

EPCS with two-factor identity proofing

Federal rules for electronic prescribing of controlled substances require identity proofing of the prescriber and two-factor authentication at the moment of signing.

OrbitRx is built to those requirements: the prescriber's identity is proofed during credentialing, each controlled prescription is signed with two factors, and the signing event is recorded in the audit trail. The prescription then routes over Surescripts to a pharmacy that is DEA-registered where applicable and licensed for the destination state.

DEA registration verified at credentialing

Every provider in the network goes through NCQA-standard primary-source credentialing, which includes verification of state licenses and, for prescribers who will write controlled prescriptions, their DEA registration and any state controlled-substance registration the destination state requires.

Monthly OIG and SAM exclusion screening continues after onboarding. Brands that bring their own providers go through the same checks.

Federal telemedicine flexibilities

Since 2020, federal flexibilities have allowed prescribers to issue controlled-substance prescriptions via telemedicine without a prior in-person evaluation in defined circumstances.

• DEA and HHS have extended those flexibilities several times; the current extension runs through December 31, 2026.
• What follows, whether a further extension, a special registration framework or a return to in-person requirements, is not settled as of this writing.
• Confirm the current status on dea.gov before building a program around it, and remember that state law can be stricter than federal law.
• This is general information, not legal advice.

Pharmacy cost passes through

Medication is billed at the pharmacy's cost to the brand with 0% markup.

• We do not add a margin to the drug, and we do not take a revenue share on the program price.
• The brand sets what the patient pays, keeps the difference and is the merchant of record on its own payment processor.
• Shipping and cold-chain packaging are part of the pharmacy's cost and pass through the same way.

What the brand pays the platform

A flat platform fee scoped at onboarding to the brand's verticals, states and expected volume covers OrbitOS, Orbit Intake, OrbitRx, the storefront, portal and native app, the provider network and compliance infrastructure.

• The agreement is month-to-month after onboarding with no exit or termination fee, and the brand owns its patients, records and data with export at any time.
• There is no published price list for the platform or for medications, because pharmacy costs vary by product, strength, pharmacy and state and change over time.
• Directional ranges are in the startup cost calculator at /tools/startup-cost-calculator; the model itself is explained at /pricing.

Why a markup-free model changes program design

When the platform earns a percentage of each prescription, its incentive is volume.

• When it earns a flat fee, its incentive is that the brand stays live and compliant.
• For the operator, 0% markup means the unit economics of a GLP-1 or TRT program are transparent: pharmacy cost, provider visit, platform fee, acquisition cost, and the price you set.
• You can model it on a napkin, which is harder to do when a vendor's cut is buried in the drug price.

Nonresident licensure

Most states require a pharmacy located elsewhere to hold a nonresident pharmacy license before dispensing to their residents, and several add separate permits or pharmacist-in-charge requirements for sterile compounding.

Requirements, fees and renewal cycles differ by state and change often. No single pharmacy holds every license for every product, so a program that promises all 50 states from one pharmacy is either not shipping everywhere or not shipping lawfully everywhere.

What routing does with that fact

OrbitRx matches licensure per ship-to state at the moment of routing.

• A compounded preparation for a patient in a state with strict sterile-compounding permits goes to a pharmacy that holds that permit; a manufactured product for a patient in the next state may go somewhere else entirely.
• The patient sees one brand and one tracking number; the compliance work happens underneath.
• When a state changes its rules, routing changes with it, and the brand does not have to renegotiate contracts.

Licensure is not the whole picture

State law also governs whether a given telehealth program is lawful at all: corporate practice of medicine rules, telehealth modality rules, and state-specific restrictions on compounded peptides and GLP-1s.

The state legality checker at /tools/state-legality-checker gives a program-level view, and the compliance page at /compliance describes how the MSO and friendly-PC structure keeps the brand on the right side of those rules.

Partner pharmacy names and counts

We do not list partner pharmacies or publish how many are in the network.

• The network is contracted and re-verified on an ongoing basis, and a public list goes stale the week it is published.
• More importantly, a partner's name is not what protects the brand; the LegitScript certification of the network, the per-state licensure matching at routing, and the DEA registration of the pharmacies that handle controlled substances are.
• Partners under evaluation receive the specifics relevant to their states and products during onboarding.

Turnaround and delivery days

We do not publish fill or transit times.

They depend on the product, the pharmacy's queue, the destination and the carrier. The patient portal shows live tracking per order, and OrbitOS reporting shows the brand its actual dispense-to-delivery distribution, which is more useful than a number on a marketing page.

Drug prices

Medication costs vary by product, strength, pharmacy and state and change when manufacturers and compounders change theirs.

Because they pass through at 0% markup, publishing a price list would be publishing someone else's price list. Current pass-through costs for a brand's planned formulary are shared during onboarding.